|25.63||+0.0400||+0.16%||Vol 339.86K||1Y Perf 17.01%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||27.40||Analyst Rating||Strong Buy 1.50|
|Potential %||6.91||Finscreener Ranking||+ 37.27|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||+ 36.80|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||☆ 27.45|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||51.12||Earnings Rating||Sell|
|Market Cap||835.82M||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.11|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||315.41K|
|Avg. Monthly Volume||343.02K|
|Avg. Quarterly Volume||289.81K|
Collegium Pharmaceutical Inc. (NASDAQ: COLL) stock closed at 25.63 per share at the end of the most recent trading day (a 0.16% change compared to the prior day closing price) with a volume of 339.86K shares and market capitalization of 835.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 234 people. Collegium Pharmaceutical Inc. CEO is Joseph J. Ciaffoni.
The one-year performance of Collegium Pharmaceutical Inc. stock is 17.01%, while year-to-date (YTD) performance is 10.47%. COLL stock has a five-year performance of 33.56%. Its 52-week range is between 20.83 and 30.22, which gives COLL stock a 52-week price range ratio of 51.12%
Collegium Pharmaceutical Inc. currently has a PE ratio of -26.30, a price-to-book (PB) ratio of 4.88, a price-to-sale (PS) ratio of 2.80, a price to cashflow ratio of 10.80, a PEG ratio of -1.32, a ROA of -4.68%, a ROC of -1.24% and a ROE of -20.90%. The company’s profit margin is -5.33%, its EBITDA margin is 27.80%, and its revenue ttm is $334.31 Million , which makes it $9.96 revenue per share.
Of the last four earnings reports from Collegium Pharmaceutical Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.11 for the next earnings report. Collegium Pharmaceutical Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Collegium Pharmaceutical Inc. is Strong Buy (1.5), with a target price of $27.4, which is +6.91% compared to the current price. The earnings rating for Collegium Pharmaceutical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Collegium Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Collegium Pharmaceutical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.53, ATR14 : 0.72, CCI20 : 63.86, Chaikin Money Flow : -0.09, MACD : 0.88, Money Flow Index : 71.97, ROC : 4.70, RSI : 66.90, STOCH (14,3) : 78.21, STOCH RSI : 0.12, UO : 47.67, Williams %R : -21.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Collegium Pharmaceutical Inc. in the last 12-months were: Dreyer Scott (Sold 31 158 shares of value $844 305 ), Joseph Ciaffoni (Option Excercise at a value of $1 397 657), Joseph Ciaffoni (Sold 162 606 shares of value $3 749 892 ), Kuhlmann Shirley (Sold 39 795 shares of value $976 833 ), Kuhlmann Shirley R. (Sold 17 984 shares of value $390 633 ), Michael T. Heffernan (Option Excercise at a value of $4 623 167), Michael T. Heffernan (Sold 298 612 shares of value $6 727 097 ), Scott Dreyer (Sold 17 834 shares of value $488 554 ), Shirley R. Kuhlmann (Sold 21 811 shares of value $586 280 ), Tupper Colleen (Sold 31 640 shares of value $752 083 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.